Molecular genetics related to non-Hodgkin lymphoma

Abstract

Non-Hodgkin lymphoma (NHL) is a serious disease, with a high proportion of mortality. Molecular genetic abnormalities are very common in NHL, but specific characterization in accordance to molecular genetics for lymphoma subtypes is not yet completed. This article summarizes the relationship between B- and T-NHL and molecular genetics. We focus on NHL subtypes and emphasize its features to figure out what is exposed about NHL genetics. The basis of this method is collection of biological specimens for genomic and genetic analyses. This summary may help to prompt prediction of outcomes and guide therapy in the future.

Immune polychemotherapy regimen choice in B-cell non-Hodgkin lymphoma of high and low malignancy based on the identification of the mutational c-myc and BCL 2 genes

“…The prognostic effect of MYC/BCL 2 coexpression was statistically significant when other factors were considered (e.g., IPI, belonging to the GCB/non-GCB subtype, the presence of c-myc/BCL 2 rearrangements). [12][13][14][15] The author's study of the molecular genetic features of BCL revealed a biological variety and identified several genetic subtypes of this disease, which differ in course and prognosis. Subtypes of B-cell lymphoma develop from genetic disorders in the course of maturation of B-lymphocytes and are described by blocking apoptosis, impaired regulation of BCL 2, loss of function of BCL 6, deletion of p53 and increased cell proliferation, impaired regulation of c-myc.…”